Engineered IL-7 Synergizes with IL-12 Immunotherapy to Prevent T Cell Exhaustion and Promote Memory without Exacerbating Toxicity

Scientists showed that the combination of engineered, tumor matrix-binding IL-7 and IL-12 achieves remarkable anticancer effects by activating complementary pathways without inducing any additive immunotoxicity.